ArticleBMC infectious diseases2025
A preliminary survey on the use of ART among blood donors in Shenzhen China and its implications to blood safety.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
importanceThe recent introduction of the AIDS pre-exposure or post-exposure prophylaxis (PrEP/PEP) medication has sparked fear of the possible increase of human immunodeficiency virus (HIV) and Treponema pallidum (TP) transfusion-transmission risk due to the potential administration of antiretroviral therapy (ART) in blood donors. However, the extent to which ART drugs are currently being utilized by blood donors in China remains to be clarified.
objectiveTo assess the prevalence of ART drug use in individuals who attempted to donate blood but were eventually rejected due to anti-HIV and/or anti-Treponema pallidum (anti-TP) reactive in Shenzhen, China and to elucidate the characteristics of these high-risk cohorts using anonymised individual-level data.
designHigh pressure liquid chromatography coupled with tandem mass spectrometry (HPLC-MS/MS) was used to measure the concentrations of 8 ART drugs in plasma samples collected from the following 5 groups: Group-A (individuals with anti-HIV screened reactive who regularly take ART drugs, n = 3) and their gradient diluted samples, Group-B (repeated blood donors, n = 86), Group-C (anti-HIV reactive/anti-TP non-reactive screened individuals, n = 77), Group-D (anti-HIV non-reactive/anti-TP reactive screened individuals, n = 353) and Group-E (anti-HIV reactive/anti-TP reactive screened individuals, n = 23). And they were all identified from 440 000 screened individuals who came to donate in Shenzhen Blood Center from 2019 to 2023.
resultsNo ART drugs were detected in all the 86 plasma samples from repeated blood donors (Group-B) or in 353 plasma samples from anti-HIV non-reactive/anti-TP reactive screened individuals (Group-D). 3 positive ART drugs (Efavirenz, lamivudine, lopinavir, ritonavir, tenofovir and zidovudine) samples in Group-C (anti-HIV reactive/anti-TP non-reactive, 3 out of 77 screened), and 1 sample with efavirenz, lamivudine and tenofovir in Group-E (anti-HIV reactive/ anti-TP reactive, 1 out of 23 screened) were detected in 1:2 pooled plasma samples. The ART drugs could still be detected even after the pooled plasma was further diluted at 1:6. In addition, HIV RNA was not detectable in one of the 4 ART positive screened individuals.
conclusionART drugs were detected in 4(4/100) anti-HIV reactive plasma samples screened from 440 000 donations in Shenzhen, which indicated some HIV-infected people who take ART drugs donate blood without disclosing their health and medical histories and this may endanger blood safety because ART may compromise current screening strategies by suppressing HIV RNA replication below the detectable level. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.